Anuh Pharma Ltd
As of 16 Oct 2026, Anuh Pharma is in Stage 2 — advancing, the uptrend phase, in week 10 (since 10 Aug 2026). It closed at ₹82.57, 14.6% below its 52-week high and above its 200-day average, which is rising. In Health Care, 40.0% of stocks are in Stage 2.
Anuh Pharma Limited engages in the manufacture and sale of bulk drugs and chemicals in India. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #38 of 59 in Pharmaceuticals · #46 of 70 in Health Care
Is ANUHPHR early, or has it already run? Pro answers that for every NSE stock, after every close.
About this companyHealth Care· Pharmaceuticals
Anuh Pharma Limited engages in the manufacture and sale of bulk drugs and chemicals in India. It offers active pharmaceutical ingredients, including macrolides, anti-TB, anti-bacterial, anti-asthmatics, anti-diabetics, intermediates, expectorant, quinolones, anti-malarial, anti-gout, anti-biotic, anti-platelet, and antihistamines; and corticosteroids, including anti-inflammatory, immunosuppressant, anti-pruritic, anti-mitotic. The company also develops products, such as coagulants, gastrointestinal, anti convulsants, and cholesterol drugs. It also exports its products. The company was incorporated in 1960 and is headquartered in Mumbai, India.
Visit company website →All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.